ArticleBMC psychiatry2026
Objective diagnosis and treatment outcome prediction in major depressive disorder based on a machine learning framework with dried-serum NIRS digital biomarkers.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMajor depressive disorder (MDD) involves complex interactions across multiple physiological systems, necessitating a comprehensive and integrative perspective for objective diagnosis and personalized treatment. Although multi-omics technologies provide broad molecular insights, their high cost and complexity limit clinical translation.
methodsWe developed a cost-effective and practical machine learning framework using digital biomarkers from dried serum near-infrared spectroscopy (NIRS) for MDD diagnosis and antidepressant treatment outcome prediction. A total of 126 MDD patients and 86 healthy controls were enrolled. Six feature selection methods were systematically compared via rigorous nested cross-validation, and the final models were constructed using partial least squares discriminant analysis, evaluated with decision curve analysis (DCA), and deployed as a clinical diagnostic and decision-support web tool.
resultsDried serum NIRS provided sufficient biochemical information to support the development of accurate diagnostic and treatment outcome prediction models. Competitive adaptive reweighted sampling (CARS) combined with SHapley Additive exPlanations (SHAP) emerged as the best-performing approach for identifying decisive wavelengths. The diagnostic model achieved an AUC of 0.91 (95% CI: 0.86–0.95, accuracy 0.85, sensitivity 0.87, specificity 0.83), and the treatment outcome prediction model reached an AUC of 0.90 (95% CI: 0.80–0.97, accuracy 0.84, sensitivity 0.83, specificity 0.84). DCA confirmed substantial net clinical benefit across wide probability ranges. SHAP analysis revealed that the diagnostic model was associated with multiple biomolecular components, especially proteins, whereas the treatment outcome prediction model was primarily influenced by proteins and carbohydrates.
conclusionsTo our knowledge, this study is the first to comprehensively characterize dried-serum NIRS and demonstrate its potential utility in psychiatry, paving a promising avenue for spectral digital biomarker-based precision diagnosis and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.